1. Show article details.

    BRIEF-Magenta Therapeutics Appoints Steve Mahoney As Chief Financial And Operating Officer

    Reuters – 8:28 AM ET 11/09/2020

    Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS APPOINTS STEVE MAHONEY AS CHIEF FINANCIAL AND OPERATING OFFICER Source text for Eikon: Further company coverage:

  2. Show article details.

    Magenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating Officer

    Business Wire – 8:00 AM ET 11/09/2020

    Magenta Therapeutics (MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of Steve Mahoney as Chief Financial and Operating Officer.

  3. Show article details.

    BRIEF-Magenta Therapeutics Posts Quarterly Net Loss Per Share, Basic And Diluted $0.37

    Reuters – 8:29 AM ET 11/05/2020

    Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND THIRD QUARTER FINANCIAL RESULTS. * Magenta Therapeutics Inc (MGTA) - QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.37. * Magenta Therapeutics Inc (MGTA) - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF SEPTEMBER 30, 2020, WERE $161.7 MILLION.

  4. Show article details.

    Magenta Therapeutics Reports Recent Business Highlights and Third Quarter Financial Results

    Business Wire – 8:00 AM ET 11/05/2020

    – Magenta advanced its MGTA-145 mobilization program, with two Phase 2 trials to be initiated by end of 2020; the Company’s MGTA-117 conditioning program is on track to file an IND and generate clinical data in 2021; – Magenta announced appointment of Lisa M. Olson, Ph.D., as Head of Research and Chief Scientific Officer – – Magenta named co-recipient of a U19 grant from the National Institut...

  5. Show article details.

    Magenta Therapeutics Announces Multiple Presentations Across Stem Cell Transplant Portfolio at The American Society of Hematology (ASH) Annual Meeting

    Business Wire – 11:02 AM ET 11/04/2020

    – Magenta will present a total of five abstracts, including an oral presentation highlighting clinical and preclinical data across its mobilization and conditioning pipeline – – Oral presentation of completed Phase I clinical trial confirms that MGTA-145, a novel biologic, robustly mobilized large numbers of functional hematopoietic stem cells for autologous and allogeneic stem cell transplant ...

  6. Show article details.

    Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in September

    Business Wire – 8:00 AM ET 09/11/2020

    Magenta Therapeutics (MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in the following September investor conferences: Live webcasts can be accessed on the Magenta Therapeutics (MGTA) website at https://investor.magentatx.com/events-and-presentations.

  7. Show article details.

    BRIEF-Magenta Therapeutics Named Co-Recipient Of Grant From NIH To Explore Approaches To Cure HIV

    Reuters – 12:56 PM ET 09/02/2020

    Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS NAMED CO-RECIPIENT OF GRANT FROM THE NATIONAL INSTITUTES OF HEALTH TO EXPLORE USE OF NOVEL TARGETED CONDITIONING AGENTS WITH GENE EDITING APPROACHES TO CURE HIV. * MAGENTA - WILL UTILIZE CD45, CD117 ADC CONDITIONING AGENTS, STEM CELL BIOLOGY PLATFORM TO IDENTIFY STRATEGY FOR TRANSPLANT IN HIV PATIENTS Source text for Eikon: Further company coverage:

  8. Show article details.

    Magenta Therapeutics Named Co-Recipient of Grant from the National Institutes of Health to Explore Use of Novel Targeted Conditioning Agents with Gene Editing Approaches to Cure HIV

    Business Wire – 12:00 PM ET 09/02/2020

    – NIH grant funds an interdisciplinary effort among researchers from University of Southern California; University of Washington and Fred Hutchinson Cancer Research Center; Harvard University and Massachusetts General Hospital; the Ragon Institute; and Magenta Therapeutics (MGTA) – – Magenta will utilize its tool CD45 and CD117 antibody-drug conjugate conditioning agents, as well as its stem cell biol...

  9. Show article details.

    BRIEF-Magenta Therapeutics Appoints Chief Scientific Officer And Senior Vice President, Head Of Regulatory And Quality Announces Transition Of Jason Ryan, Chief Operating And Financial Officer

    Reuters – 8:09 AM ET 09/02/2020

    Magenta Therapeutics Inc (MGTA): * MAGENTA THERAPEUTICS APPOINTS LISA M. OLSON AS CHIEF SCIENTIFIC OFFICER AND KEVIN B. JOHNSON AS SENIOR VICE PRESIDENT, HEAD OF REGULATORY AND QUALITY; ANNOUNCES TRANSITION OF JASON RYAN, CHIEF OPERATING AND FINANCIAL OFFICER. * Magenta Therapeutics Inc (MGTA) - JASON RYAN, CHIEF OPERATING AND FINANCIAL OFFICER, WILL STEP DOWN FROM THAT ROLE AT END OF SEPTEMBER.

  10. Show article details.

    Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality; Announces Transition of Jason Ryan, Chief Operating and Financial Officer

    Business Wire – 8:00 AM ET 09/02/2020

    Magenta Therapeutics (MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of two new executives, Lisa M. Olson, Ph.D., as Chief Scientific Officer and Kevin B. Johnson, Ph.D., as Senior Vice President, Head of Regulatory and Quality.

  11. Show article details.

    Magenta Therapeutics Announced It Will Present Clinical and Pre-Clinical Data from Across Immune and Blood System Reset Portfolio at European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting

    Business Wire – 8:00 AM ET 08/31/2020

    – Magenta to present five abstracts showcasing data across clinical and pre-clinical pipeline, including mobilization and conditioning programs – – Phase I clinical trial results confirm that MGTA-145 demonstrates same-day mobilization and collection of highly functional hematopoietic stem cells for transplant – – Preclinical data from studies of Magenta’s CD45-ADC conditioning agen...

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Nov
    05

    MGTA announced Q3 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.